



## **Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference**

May 7, 2024

CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.

A live webcast of the fireside chat will be available [here](#) and in the investors section of the company's website at [www.designtx.com](http://www.designtx.com). The webcast will be archived for 30 days following the presentation.

### **About Design Therapeutics**

Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company's GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy, Huntington's disease and myotonic dystrophy type-1. Discovery efforts are underway for multiple genomic medicines. For more information, please visit [designtx.com](http://designtx.com).

### **Contact:**

Renee Leck  
THRUST Strategic Communications  
[renee@thrustsc.com](mailto:renee@thrustsc.com)